These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19382058)

  • 1. Problems of the use of pseudoephedrine by athletes.
    Pokrywka A; Tszyrsznic W; Kwiatkowska DJ
    Int J Sports Med; 2009 Aug; 30(8):569-72. PubMed ID: 19382058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of urinary concentrations of pseudoephedrine and cathine after therapeutic administration of pseudoephedrine-containing medications to healthy subjects: implications for doping control analysis of these stimulants banned in sport.
    Barroso O; Goudreault D; Carbó Banús ML; Ayotte C; Mazzoni I; Boghosian T; Rabin O
    Drug Test Anal; 2012 May; 4(5):320-9. PubMed ID: 21548139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of the urinary concentration of ephedrines in anti-doping analysis: determination of pseudoephedrine, cathine, and ephedrine after administration of over-the-counter medicaments.
    Strano-Rossi S; Leone D; de la Torre X; Botrè F
    Ther Drug Monit; 2009 Aug; 31(4):520-6. PubMed ID: 19571776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretation of urinary concentrations of pseudoephedrine and its metabolite cathine in relation to doping control.
    Deventer K; Van Eenoo P; Baele G; Pozo OJ; Van Thuyne W; Delbeke FT
    Drug Test Anal; 2009 May; 1(5):209-13. PubMed ID: 20355197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudoephedrine and preexercise feeding: influence on performance.
    Pritchard-Peschek KR; Osborne MA; Slater GJ; Taaffe DR; Jenkins DG
    Med Sci Sports Exerc; 2013 Jun; 45(6):1152-7. PubMed ID: 23274597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Athletes' knowledge and views on OTC medication.
    Mottram D; Chester N; Atkinson G; Goode D
    Int J Sports Med; 2008 Oct; 29(10):851-5. PubMed ID: 18401811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoephedrine and circadian rhythm interaction on neuromuscular performance.
    Pallarés JG; López-Samanes Á; Fernández-Elías VE; Aguado-Jiménez R; Ortega JF; Gómez C; Ventura R; Segura J; Mora-Rodríguez R
    Scand J Med Sci Sports; 2015 Dec; 25(6):e603-12. PubMed ID: 25515692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of caffeine levels in urine in different sports in relation to doping control before and after the removal of caffeine from the WADA doping list.
    Van Thuyne W; Delbeke FT
    Int J Sports Med; 2006 Sep; 27(9):745-50. PubMed ID: 16586337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pseudoephedrine on 800-m-run times of female collegiate track athletes.
    Berry C; Wagner DR
    Int J Sports Physiol Perform; 2012 Sep; 7(3):237-41. PubMed ID: 22158915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydration and urinary pseudoephedrine levels after a simulated team game.
    Jolley D; Dawson B; Maloney SK; White J; Goodman C; Peeling P
    Int J Sport Nutr Exerc Metab; 2014 Jun; 24(3):325-32. PubMed ID: 24458099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Doctors belonging to the Senegalese Association of Sport Medicine and doping in sports: survey on knowledge and attitudes].
    Dièye AM; Diallo B; Fall A; Ndiaye M; Cissè F; Faye B
    Sante; 2005; 15(3):167-70. PubMed ID: 16207578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation.
    Chan KH; Hsu MC; Chen FA; Hsu KF
    J Anal Toxicol; 2009 Apr; 33(3):162-6. PubMed ID: 19371465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
    Nikolopoulos DD; Spiliopoulou C; Theocharis SE
    Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
    Wolfarth B; Wuestenfeld JC; Kindermann W
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulants and doping in sport.
    Thevis M; Sigmund G; Geyer H; Schänzer W
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):89-105, ix. PubMed ID: 20122452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Illicit drugs and cardiac arrhythmias in athletes.
    Furlanello F; Serdoz LV; Cappato R; De Ambroggi L
    Eur J Cardiovasc Prev Rehabil; 2007 Aug; 14(4):487-94. PubMed ID: 17667636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone abuse in sports: the antidoping perspective.
    Barroso O; Mazzoni I; Rabin O
    Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast analysis of doping agents in urine by ultra-high-pressure liquid chromatography-quadrupole time-of-flight mass spectrometry. II: Confirmatory analysis.
    Badoud F; Grata E; Perrenoud L; Saugy M; Rudaz S; Veuthey JL
    J Chromatogr A; 2010 Jun; 1217(25):4109-19. PubMed ID: 19939397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene doping.
    Haisma HJ; de Hon O
    Int J Sports Med; 2006 Apr; 27(4):257-66. PubMed ID: 16572366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.